Letter: Regarding the Gulf CALLS Study – Baseline Non-HDL-C as a Residual-Risk Marker

Abstract

Get full access to this article

View all access options for this article.

References

Mahmeed

Kindi

Al-Sarraf

, et al. Residual cardiovascular risk associated with non-HDL-C in statin-treated patients: data from the Gulf TriglyCeride And ResiduaL CardiovascuLar RiSk (Gulf CALLS) cohort. Angiology. 2026;2026:33197261422789.

Hansen

Mortensen

Warnakula Olesen

, et al. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study. Lancet Reg Health Eur. 2024;36:100774.

Brunner

Waldeyer

Ojeda

, et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019;394(10215):2173-2183.

Guan

Shi

, et al. Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study. Front Cardiovasc Med. 2023;10:1105342.

Johannesen

CDL

Langsted

Nordestgaard

Mortensen

. Excess apolipoprotein B and cardiovascular risk in women and men. J Am Coll Cardiol. 2024;83(23):2262-2273.

Soffer

Marston

Maki

, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647-e663.